Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · October 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04606446). This is a study registration, not published results. Lead sponsor: Pfizer. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 320 participants (ESTIMATED). Conditions: Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer. Interventions: DRUG: PF-07248144; DRUG: Fulvestrant; DRUG: Letrozole; DRUG: Palbociclib; DRUG: PF-07220060; DRUG: PF-07850327, ARV-471, vepdegestrant. Primary outcome measures: Number of participants with dose-limiting toxicities in the Dose Escalation Arms. , Up to 29 days; Safety and Tolerability as assessed by adverse event monitoring for participants enrolled in the Dose Escalation Arms. , Up to 24 months; Safety and Tolerability through monitoring of laboratory assessments for participants enrolled in the Dose Escalation Arms. , Up to 24 months; Safety and Tolerability as assessed by adverse event monitoring for participants enrolled in the Dose Expansion Arms , Up to 24 months; Safety and Tolerability through monitoring of laboratory assessments for participants enroled in the Dose Expansion Arms , Up to 24 months. Brief summary: This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other agents